A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-15. Anything still debated is marked as such rather than presented as settled.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
It mandates that "the use of artificial intelligence efforts should not compromise the integrity of nuclear safeguards, whether through the functionality of weapons systems, the validation of communications from command authorities, or the principle of requiring positive human actions in execution of decisions by the President with respect to the employment of nuclear weapons." In February 2026, the Trump Administration publicly reaffirmed that nuclear weapons decisions will remain subject to human control, with a senior Pentagon official reiterating the "Department's policy that there is a human in the loop on all decisions on whether to employ nuclear weapons". In September 2025, the French Center for AI Safety (CeSIA), The Future Society and the Center for Human-Compatible AI (CHAI) published a global call for AI red lines urging governments to reach a binding international agreement prohibiting unacceptable AI uses by the end of 2026. The declaration was initially signed by 200 prominent figures including 10 Nobel Prize winners, and was announced by Maria Ressa at the United Nations General Assembly. In December 2025, President Donald Trump signed an executive order to establish a "National Policy Framework for Artificial Intelligence". The executive order discouraged state governments from regulating AI, urging Congress to pass a law pre-empting such regulations. The White House cited economic and national security concerns as reasons for the measure, while some criticized Trump for creating uncertainty for AI regulation. On July 6, 2026, Illinois Governor J.B.
=== Possible future treatments === A peptide that prevents and treats citrus greening disease in greenhouse trials was being tested in field trials in 2021; an enhanced injectable version of the product was being developed in 2020. Two types of antisense oligonucleotide (FANA and Morpholinos) can be delivered efficiently into citrus trees, suppressing their RNA targets. FANA can suppress 'Candidatus Liberibacter asiaticus' in citrus trees. Morpholinos can suppress CLas in infected citrus trees and the psyllid vectors. Furthermore, the PPMOs designed to endosymbiotic bacteria of the psyllid vectors, can reduce psyllid populations by targeting and suppressing the insects endosymbionts, the bacteria which are essential for psyllid survival. Morpholinos must be covalently linked with a charged molecule or peptide, to enter bacteria. The target RNA is made susceptible to cleavage by ribonuclease P (RNase-P). Researchers at the Chinese Academy of Sciences found that the E3 ubiquitin ligase PUB21 acts as an essential susceptibility gene, marking the MYC2 transcription factor for degradation. Introduction of a dominant negative variant of PUB21 was successful in conferring resistance to HLB by stabilizing MYC2 levels.
Jack Watson was born on May 2, 1939, in Casey, Iowa, to Jesse H. and Anne Watson. Jack grew up in a town of about 1,000 residents in northern Iowa, Nora Springs. His father was the area's school superintendent and he had one brother. After graduating from Nora Springs High School 1957, he went to Iowa State University, majoring in chemistry and taking part in the University’s Air Force ROTC program for four years which accounts for the four years he spent on active duty in California and Texas. Before serving his Air Force obligation, after graduation Iowa State with a degree in Chemical Technology in 1961, he went to graduate school at the Massachusetts Institute Technology (MIT). At MIT, Watson was a PhD candidate in the laboratory of Klaus Biemann, one of the most notable experts in organic mass spectrometry at the time. As soon as he graduated from MIT, Watson reported for duty in the United States Air Force in the San Francisco Bay area. A friend of his from high school, introduced Watson to Judith Sjoberg. Not long after that, they were married and moved to Brooks Air Base in San Antonio, Texas. After completing his tour of duty in the Air Force, Watson took a one-year postdoctoral position in Strasbourg France at the Institut de Chimie, Université de Strasbourg under the direction of Robert Wolf. During this time and through the licensing of the Watson-Biemann gas separator to Thomson-CSF, for use in a gas chromatograph-mass spectrometer they ware manufacturing at the time, Watson made everlasting ties to the French Mass Spectrometry community.
== History == ETH-LAD was first described in the scientific literature by Tetsukichi Niwaguchi and colleagues by 1976. Subsequently, its preclinical pharmacology was studied and described by Andrew J. Hoffman and David E. Nichols in 1985. ETH-LAD's properties and effects in humans were assessed by Alexander Shulgin. These observations were reported via personal communication by Nichols in 1986, later described by Shulgin himself in a 1994 literature review, and described in-depth by Shulgin himself in his 1997 book TiHKAL (Tryptamines I Have Known and Loved). ETH-LAD was encountered as a novel designer drug in Europe by 2016.
Biochemistry laboratories often use in vitro studies to explore ATP-dependent molecular processes. ATP analogs are also used in X-ray crystallography to determine a protein structure in complex with ATP, often together with other substrates. Enzyme inhibitors of ATP-dependent enzymes such as kinases are needed to examine the binding sites and transition states involved in ATP-dependent reactions. Most useful ATP analogs cannot be hydrolyzed as ATP would be; instead, they trap the enzyme in a structure closely related to the ATP-bound state. Adenosine 5′-(γ-thiotriphosphate) is an extremely common ATP analog in which one of the gamma-phosphate oxygens is replaced by a sulfur atom; this anion is hydrolyzed at a dramatically slower rate than ATP itself and functions as an inhibitor of ATP-dependent processes. In crystallographic studies, hydrolysis transition states are modeled by the bound vanadate ion. Caution is warranted in interpreting the results of experiments using ATP analogs, since some enzymes can hydrolyze them at appreciable rates at high concentration.
Sources: en.wikipedia.org
The SC was decommissioned in 1990, after having been in operation for more than three decades. As a consequence, the collaboration decided to relocate the ISOLDE facility to the Proton Synchrotron, and place the targets in an external beam from its 1 GeV booster. The construction of the new ISOLDE experimental hall started about three months prior to the decommissioning of the SC. With the relocation also came several upgrades. The most notable being the installation of two new magnetic dipole mass separators. One general-purpose separator with one bending magnet and the other one is a high-resolution separator with two bending magnets. The latter one is a reconstructed version of the ISOLDE 3. The first experiment at the new facility, known as ISOLDE PSB, was performed on 26 June 1992. In May 1995, two industrial robots were installed in the facility to handle the targets and ion sources units without human intervention.
3D bioprinting generally follows three steps: pre-bioprinting, bioprinting, and post-bioprinting. Pre-bioprinting is the process of creating a model that the printer will later create and choosing the materials that will be used. One of the first steps is to obtain a biopsy of the organ, to sample cells. Common technologies used for bioprinting are computed tomography (CT) and magnetic resonance imaging (MRI). To print with a layer-by-layer approach, tomographic reconstruction is done on the images. The now-2D images are then sent to the printer to be made. Once the image is created, certain cells are isolated and multiplied. These cells are then mixed with a special liquefied material that provides oxygen and other nutrients to keep them alive. This aggregation of cells does not require a scaffold, and is required for placing in the tubular-like tissue fusion for processes such as extrusion.
Modern techniques using increasingly precise Thermal-Ionization (TIMS) and Collsion-Cell Multi-Collector Inductively-coupled plasma mass spectrometry (CC-MC-ICP-MS) techniques, however, have been used for successful K–Ca dating similar in method to Rb-Sr dating, as well as determining K losses from the lower continental crust and for source-tracing calcium contributions from various geologic reservoirs. Stable isotope variations of calcium (most typically 44Ca/40Ca or 44Ca/42Ca, denoted 'δ44Ca' and 'δ44/42Ca' in delta notation) are also widely used across the natural sciences for a number of applications, ranging from early determination of osteoporosis to quantifying volcanic eruption timescales. Other applications include: quantifying carbon sequestration efficiency in CO2 injection sites and understanding ocean acidification, exploring both ubiquitous and rare magmatic processes, such as formation of granites and carbonatites, tracing modern and ancient trophic webs including in dinosaurs, assessing weaning practices in ancient humans, and a plethora of other emerging applications.
As Deka Yellow, Jasmine wields the D-Knuckle and the D-Stick (ディースティック, Dī Sutikku) jitte, which can combine to form the D-Shot (ディーショット, Dī Shotto) handgun and allow her to perform the Twin Cam Shot (ツインカムショット, Tsuin Kamu Shotto) attack alongside Umeko. Using the SP License, she can perform the Mirage Dimension (ミラージュディメンション, Mirāju Dimenshon) attack. Jasmine is portrayed by Ayumi Kinoshita (木下 あゆ美, Kinoshita Ayumi). As a child, she is portrayed by Risa Asagi (浅黄 理紗, Asagi Risa).
Sources: en.wikipedia.org
Oxidative phosphorylation or electron transport-linked phosphorylation or terminal oxidation, is the metabolic pathway in which cells use enzymes to oxidize nutrients, thereby releasing chemical energy in order to produce adenosine triphosphate (ATP). In eukaryotes, this takes place inside mitochondria. Almost all aerobic organisms carry out oxidative phosphorylation. This pathway is so pervasive because it releases more energy than fermentation. In aerobic respiration, the energy stored in the chemical bonds of glucose is released by the cell in glycolysis and subsequently the citric acid cycle, producing carbon dioxide and the energetic electron donors NADH and FADH₂. Oxidative phosphorylation uses these molecules and O2 to produce ATP, which is used throughout the cell whenever energy is needed. During oxidative phosphorylation, electrons are transferred from the electron donors to a series of electron acceptors in a series of redox reactions ending in oxygen, whose reaction releases half of the total energy. In eukaryotes, these redox reactions are catalyzed by a series of protein complexes within the inner mitochondrial membrane; whereas, in prokaryotes, these proteins are located in the cell's plasma membrane. These linked sets of proteins are called the electron transport chain. In mitochondria, five main protein complexes are involved, whereas prokaryotes have various other enzymes, using a variety of electron donors and acceptors.
=== Industrial chemicals === Industrial chemicals from various industries produce harmful chemicals that are known to cause harm to human health and the environment. Common industrial chemicals, like 1,4-Dioxanes, Perfluorooctane sulfonate (PFOS) and Perfluorooctanoic acid (PFOA), are commonly found in various water sources.
=== Computed tomography === Computed tomography angiography has a 98-100% sensitivity and specificity for diagnosing aortic dissections. It is the initial recommended test and also the most commonly used imaging test in the diagnosis of aortic dissections, being utilized in 74-77% of cases in population based studies.
== Career == In 1896, Folin returned to Sweden and began his research in the laboratory of Prof. Olof Hammarsten (1841-1932) at Uppsala University. In 1897, he left to work in the laboratory of the chemist, Ernst Leopold Salkowski at the Pathological Institute of Charité (Charité - Universitätsmedizin Berlin) in Berlin, Germany. In 1890, he became a citizen of the United States. He joined the University of Chicago gaining his Ph.D. in 1898.
On 8 December 1991, the remaining leaders of the republics signed the Belavezha Accords which agreed that the USSR would be dissolved and replaced with a Commonwealth of Independent States. On 25 December, President Gorbachev announced his resignation and turned all executive powers over to Yeltsin. The next day the Council of Republics voted to dissolve the Union. Since then, the republics have been governed independently with some reconstituting themselves as liberal parliamentary republics and others, particularly in Central Asia, devolving into highly autocratic states under the leadership of the old Party elite.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.